Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.

November 20, 2023 Please see attachment. Contact informationInvestor RelationsAnders Mohr Christensen +45 2515 2364dkamc@chr-hansen.comPress RelationsSanne Seyer-Hansen +45 6038 6207dksash@chr-hansen.comAttachment 2023_Update on the merger approval process for the combination of Novozymes and Chr. Hansen
Comunicato Precedente

next
Comunicato Successivo

next
Preferisci Informazione.News su Google

November 20, 2023


Please see attachment.


Contact information

Investor Relations
Anders Mohr Christensen
+45 2515 2364
dkamc@chr-hansen.com

Press Relations
Sanne Seyer-Hansen
+45 6038 6207
dksash@chr-hansen.com

Attachment

  • 2023_Update on the merger approval process for the combination of Novozymes and Chr. Hansen

Per maggiori informazioni
Sito Web
chr-hansen.com

Ufficio Stampa

 Nasdaq GlobeNewswire (Leggi tutti i comunicati)
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti

Allegati
Slide ShowSlide Show
Non disponibili
;